Citations

Mayo Clinic

Clear

47 citation(s) found for "Fahy, J V".

DNA Sequencing Analysis of Cystic Fibrosis Transmembrane Regulator Gene Identifies Cystic Fibrosis-Associated Variants in the Severe Asthma Research Program
Izquierdo, Manuel, Marion, Chad R. , Moore, Wendy C. , Raraigh, Karen S. , Cutting, G., Ampleford, Elizabeth J., Hawkins, Gregory A., Castro, M., Denlinger, Loren C. , Erzurum, S.C., Fahy, J.V., Israel, Elliot , Jarjour, Nizar N. , Mauger, David, Woodruff, P., Bleecker, Eugene R. , Meyers, Deborah A. , Ortega, Victor E. , Castro, M. , Fahy, J.V., Levy, Bruce David , Wenzel, Sally E.

B60. ASTHMA AND ALLERGIC RESPONSES: CELLS, TISSUES, AND ANIMAL MODELS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A3244-A3244

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3244 Get It

Multicohort Meta-Analysis of Bronchial Epithelial Cells Classifies Asthma from Healthy Subjects and Identifies Pathways in Asthma
Lee, Inkoo, Kalesinskas, Larry, Erzurum, S.C., Fahy, J.V., Moore, W.C., Denlinger, Loren C. , Castro, M., Israel, Elliot , Jarjour, Nizar N. , Meyers, Deborah A. , Bleecker, Eugene R. , Woodruff, P., Ortega, Victor E. , Ganesan, Ananthakrishnan , Fahy, J.V., Castro, M. , Wenzel, Sally E. , Levy, Bruce David , Khatri, Purvesh

B101. VARIED OMICS TECHNIQUES APPLIED TO ALLERGIC AND RESPIRATORY TRAITS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A3472-A3472

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3472 Get It

DNA sequencing analysis of cystic fibrosis transmembrane conductance regulator gene identifies cystic fibrosis‐associated variants in the Severe Asthma Research Program
Izquierdo, Manuel, Marion, Chad R. , Moore, Wendy C. , Raraigh, Karen S. , Taylor‐Cousar, Jennifer L. , Cutting, Garry R. , Ampleford, E., Hawkins, Gregory A., Zein, Joe , Castro, Mario , Denlinger, Loren C. , Erzurum, Serpil C. , Fahy, John V. , Israel, Elliot , Jarjour, Nizar N. , Mauger, David, Wenzel, Sally E. , Woodruff, Prescott G. , Bleecker, Eugene R. , Meyers, Deborah A. , Ortega, Victor E. , Cutting, Gary R , Castro, M , Wenzel, Sally E , Levy, Bruce David , Wenzel, Sally E.

Pediatric Pulmonology | April 22, 2022 | Volume: 57 | Issue: 7 | Pages: 1782-1788

10.1002/ppul.25939 | PMID 35451201 Get It

AbstractBackgroundHeterozygote carriers of potentially pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have increased asthma risk. However, the frequency and impact of CFTR variation among individuals with asthma is unknown.ObjectiveTo determine whether potentially pathogenic CFTR variants associate with disease severity and whether individuals with two potentially pathogenic variants exist in a severe asthma‐enriched cohort.MethodsWe analyzed sequencing data spanning a 190.5Kb region of CFTR in participants from the Severe Asthma Research Program (SARP1‐3). Potentially pathogenic, rare CFTR variants (frequency < 0.05) were classified as CF‐causing or of varying clinical consequences (VVCC) (CFTR2. org). Regression‐based models tested for association between CFTR genotypes (0‐2 potentially pathogenic variants) and severity outcomes.ResultsOf 1401 participants, 9.5% (134) had one potentially pathogenic variant, occurring more frequently in non‐Hispanic white (NHW, 10.1% [84 of 831]) compared to African American individuals (AA, 5.2% [22 of 426]). We found ≥2 potentially pathogenic CFTR variants in 1.4% (19); 0.5% (4) of NHW and 2.8% (12) of AA. Potentially pathogenic CFTR variant genotypes (≥1 or ≥2 variants) were not cumulatively associated with lung function or exacerbations. In NHW, we found three F508del compound heterozygotes with F508del and a VVCC (two 5 T; TG12[c.1210‐11 T > G] and one Arg1070Trp) and a homozygote for the VVCC, 5 T; TG12.ConclusionsWe found potentially pathogenic CFTR variants within a severe asthma‐enriched cohort, including three compound heterozygote genotypes variably associated with CF in NHW individuals. These findings provide the rationale for CFTR sequencing and phenotyping of CF‐related traits in individuals with severe asthma.
DNA Sequencing Analysis of Cystic Fibrosis Transmembrane Regulator Gene Identifies Cystic Fibrosis-Associated Variants in the Severe Asthma Research Program.
Izquierdo, Manuel, Marion, Chad R. , Moore, Wendy C. , Raraigh, Karen S. , L, Jennifer Taylor-Cousar, Cutting, Garry R. , Ampleford, Elizabeth J., Hawkins, Gregory A., Zein, Joe , Denlinger, Loren C. , Erzurum, Serpil C. , Israel, Elliot , Jarjour, Nizar N. , Mauger, David, Woodruff, Prescott G. , Bleecker, Eugene R. , Meyers, Deborah A. , Ortega, Victor E. , Cutting, Gary R , Taylor‐Cousar, Jennifer L. , Castro, Mario , Fahy, John V. , Levy, Bruce David , Wenzel, Sally E.

No container title available | April 19, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.165037325.52611651/v1 Get It

Background: Heterozygote carriers of potentially pathogenic variants in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene have increased asthma risk. However, the frequency and impact of CFTR variation among individuals with asthma is unknown. Objective: To determine whether potentially pathogenic CFTR variants associate with disease severity and whether individuals with two potentially pathogenic variants exist in a severe asthma-enriched cohort . Methods : We analyzed sequencing data spanning a 190.5Kb region of CFTR in participants from the Severe Asthma Research Program (SARP1-3). Potentially pathogenic, rare CFTR variants (frequency<0.05) were classified as CF-causing or of varying clinical consequences (VVCC) (CFTR2.org). Regression-based models tested for association between CFTR genotypes (0-2 potentially pathogenic variants) and severity outcomes. Results: Of 1401 participants, 9.5% (134) had one potentially pathogenic variant, occurring more frequently in non-Hispanic white (NHW, 10.1% [84 of 831]) compared to African American individuals (AA, 5.2% [22 of 426]). We found ≥2 potentially pathogenic CFTR variants in 1.4% (19); 0.5% (4) of NHW and 2.8% (12) of AA. Potentially pathogenic CFTR variant genotypes (≥1 or ≥2 variants) were not cumulatively associated with lung function or exacerbations. In NHW, we found three F508del compound heterozygotes with F508del and a VVCC (two 5T;TG12[c.1210-11T>G] and one Arg1070Trp) and a homozygote for the VVCC, 5T;TG12. Conclusions: We found potentially pathogenic CFTR variants within a severe asthma-enriched cohort , including three compound heterozygote genotypes variably associated with CF in NHW individuals. These findings provide the rationale for CFTR sequencing and phenotyping of CF-related traits in individuals with severe asthma.
Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease
Jakub, James W. , MacArthur, Taleen A. , Fahy, Aodhnait S. , Jakub, James W

The American Surgeon™ | June 1, 2021 | Volume: 87 | Issue: 6 | Pages: 849-854

10.1177/00031348211023434 | PMID 34060947 Get It

Background Talimogene laherparepvec (TVEC) is an injectable attenuated oncolytic herpes simplex virus (HSV-1) used in the treatment of loco regionally metastatic melanoma. Lesions managed by TVEC are generally considered unresectable at time of initiation of intralesional therapy; however, a subset of patients go on to have surgical resection of loco regionally controlled disease. We sought to review our experience with surgical excision of treated lesions to offer an insight into the radiologic correlate, treatment effect, and pathological findings of intralesional TVEC therapy. Methods This is a retrospective descriptive case series of patients who underwent TVEC injection at Mayo Clinic, Rochester, MN, between October 2016 and July 2020. Institutional Institutional Review Board approval was obtained. Results Twenty-one patients underwent intralesional TVEC, met inclusion criteria, and were included in this series. Seven went on to surgical excision of the injected lesions after an initial course of TVEC. Of those 7 patients, 4 had residual melanoma in the specimen on final pathology, while 3 had a complete pathologic response. All 3 patients who had no residual disease on pathology continued to have fluorodeoxyglucose (FDG) avidity on preoperative positron emission tomography scan of the excised lesions. Discussion Despite ongoing FDG avidity on PET scan, patients who have well-controlled disease and stability over time of the injected lesions may benefit from surgical excision following a course of TVEC. This may render the patient clinically disease free and/or allow them a reprieve from TVEC treatment.
047 Penile Ring Block Using Long-Acting Liposomal Bupivicaine to Minimize Postoperative Narcotic Use After Surgery for Peyronie's Disease: A Pilot Study
Britton, Cameron J. , Bridget, Fahy, Köhler, Tobias , Ziegelmann, M., Yang, David Y. , Helo, Sevann

The Journal of Sexual Medicine | March 18, 2021 | Volume: 18 | Issue: Supplement_1 | Pages: S26-S26

10.1016/j.jsxm.2021.01.116 Get It

Construct Validation of the American Board of Anesthesiology’s APPLIED Examination for Initial Certification
Zhou, Yan , Chen, Dandan , Harman, Ann E., Isaak, Robert S. , Peterson-Layne, Cathleen, Macario, Alex, Fahy, Brenda G. , Wang, Ting , Sun, Huaping , Warner, David O.

Anesthesia & Analgesia | January 21, 2021 | Volume: 133 | Issue: 1 | Pages: 226-232

10.1213/ane.0000000000005364 | PMID 33481404 Get It

BACKGROUND: The American Board of Anesthesiology administers the APPLIED Examination as a part of initial certification, which as of 2018 includes 2 components—the Standardized Oral Examination (SOE) and the Objective Structured Clinical Examination (OSCE). The goal of this study is to investigate the measurement construct(s) of the APPLIED Examination to assess whether the SOE and the OSCE measure distinct constructs (ie, factors). METHODS: Exploratory item factor analysis of candidates’ performance ratings was used to determine the number of constructs, and confirmatory item factor analysis to estimate factor loadings within each construct and correlation(s) between the constructs. RESULTS: In exploratory item factor analysis, the log-likelihood ratio test and Akaike information criterion index favored the 3-factor model, with factors reflecting the SOE, OSCE Communication and Professionalism, and OSCE Technical Skills. The Bayesian information criterion index favored the 2-factor model, with factors reflecting the SOE and the OSCE. In confirmatory item factor analysis, both models suggest moderate correlation between the SOE factor and the OSCE factor; the correlation was 0.49 (95% confidence interval [CI], 0.42-0.55) for the 3-factor model and 0.61 (95% CI, 0.54-0.64) for the 2-factor model. The factor loadings were lower for Technical Skills stations of the OSCE (ranging from 0.11 to 0.25) compared with those of the SOE and Communication and Professionalism stations of the OSCE (ranging from 0.36 to 0.50). CONCLUSIONS: The analyses provide evidence that the SOE and the OSCE measure distinct constructs, supporting the rationale for administering both components of the APPLIED Examination for initial certification in anesthesiology.
First-Year Results of the American Board of Anesthesiology’s Objective Structured Clinical Examination for Initial Certification
Lien, Cynthia A. , Wang, Ting , Isaak, Robert S. , Peterson-Layne, Cathleen, Harman, Ann E., Macario, Alex, Gaiser, Robert R., Culley, Deborah J. , Keegan, Mark T. , Cole, Daniel J. , Fahy, Brenda G. , Dainer, Rupa J., Warner, David O. , Zhou, Yan , Suresh, Santhanam , Rathmell, James P. , Sun, Huaping

Anesthesia & Analgesia | July 31, 2020 | Volume: 131 | Issue: 5 | Pages: 1412-1418

10.1213/ane.0000000000005086 | PMID 33079864 Get It

In 2018, the American Board of Anesthesiology (ABA) became the first US medical specialty certifying board to incorporate an Objective Structured Clinical Examination (OSCE) into its initial certification examination system. Previously, the ABA’s staged examination system consisted of 2 written examinations (the BASIC and ADVANCED examinations) and the Standardized Oral Examination (SOE). The OSCE and the existing SOE are now 2 separate components of the APPLIED Examination. This report presents the results of the first-year OSCE administration. A total of 1410 candidates took both the OSCE and the SOE in 2018. Candidate performance approximated a normal distribution for both the OSCE and the SOE, and was not associated with the timing of the examination, including day of the week, morning versus afternoon session, and order of the OSCE and the SOE. Practice-based Learning and Improvement was the most difficult station, while Application of Ultrasonography was the least difficult. The correlation coefficient between SOE and OSCE scores was 0.35 ([95% confidence interval {CI}, 0.30–0.39]; P < .001). Scores for the written ADVANCED Examination were modestly correlated with scores for the SOE ( r = 0.29 [95% CI, 0.25–0.34]; P < .001) and the OSCE ( r = 0.15 [95% CI, 0.10–0.20]; P < .001). Most of the candidates who failed the SOE passed the OSCE, and most of the candidates who failed the OSCE passed the SOE. Of the 1410 candidates, 77 (5.5%) failed the OSCE, 155 (11.0%) failed the SOE, and 25 (1.8%) failed both. Thus, 207 (14.7%) failed at least 1 component of the APPLIED Examination. Adding an OSCE to a board certification examination system is feasible. Preliminary evidence indicates that the OSCE measures aspects of candidate abilities distinct from those measured by other examinations used for initial board certification.
Clinical significance of SLN benign capsular nevi in patients with melanoma
Yamashita, Thomas Szabo , Pockaj, Barbara A. , Flotte, Thomas J. , Azevedo, Rafael Ulysses de, Harmsen, William S. , Block, Matthew S. , Jakub, James W. , Yamashita, Thomas S, Fahy, Aodhnait S. , de Azevedo, Rafael U, Jakub, James W , Szabo Yamashita, Thomas , Bagaria, Sanjay P.

Journal of Surgical Oncology | July 23, 2020 | Volume: 122 | Issue: 6 | Pages: 1043-1049

10.1002/jso.26135 | PMID 33616952 Get It

AbstractBackgroundBenign capsular nevi (BCN) are not infrequent in sentinel lymph nodes (SLN) of patients with melanoma. Their prognostic significance is unknown and the literature is limited. This study evaluated the clinical significance of incidentally found BCN in these patients.MethodsA multi‐institutional retrospective review of patients undergoing SLN biopsy for cutaneous melanoma between 2000 and 2016. Patients were divided into the following groups: (a) negative SLN and no BCN, (b) negative SLN and presence of BCN, (c) positive SLN seen only on immunohistochemistry (IHC), and (d) positive SLN via hematoxylin and eosin (H&E). Outcomes measured were overall survival and any recurrence.ResultsA total of 1253 patients were identified (group 1 = 978, group 2 = 56, group 3 = 32, and group 4 = 187). Fifty‐seven percent were male and the mean age was 59.3 years. BCN was identified in 77 patients (6.2%), of which the majority was in the node‐negative group (72%). Multivariable analysis showed that BCN was associated with lower recurrence rates, though not statistically significant (hazard ratio [HR] = 0.5; P = .06). IHC‐ and H&E‐positive SLNs were associated with a higher risk of recurrence (HR = 2.4; P = .02 and 2.0, P < .0001, respectively).ConclusionPatients with BCN and negative SLN had lower recurrence rates than patients with negative SLN and no BCN. Our data suggest a possible protective effect against recurrence.